Loading
CG Oncology, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Liu Brian Guan-Chyun, was filed 29 Jun 2026.
Insider Decl.
120
Thresholds
n/a
Buy Volume
€76M
6 ops. · all time
Sell Volume
€49M
45 ops. · all time
Who traded when
BuySaleLeonard E. Post22 sales
Mulay James16 sales
Song Hong Fang5 sales
Liu Brian Guan-Chyun2 buys
Since the insiders bought
- -12.4%Entry US$71.05 · Close 21 Oct 2026 US$62.24
- -20.8%Entry US$37.95 · Close at T+365 US$30.07
- -20.8%Entry US$37.95 · Close at T+365 US$30.07
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate CG Oncology, Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$91.08.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 24,867 of 26,284 companies
16.1
score / 100
Value27
Quality6
FCF yld-2.4%
Earn yld-2.9%
EV/EBITDA·
ROE-26%
Gross mgn-15%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$62.24
Analyst consensus
13 analystsStrong buy
US$79.00Target US$91.08(+46%)US$108.00
Income statement
RevenueUS$4M
Gross profit-US$607k-15% margin
EBITDA-US$189.3M-4686% margin
Net income-US$161M-3985.0% margin
Valuation
PER (forward)-20.6x
P/Book5.3x
Beta0.28
Balance sheet & cash
Market capUS$5.5B
Total debtUS$7M
Free Cash Flow-US$132.5M
Debt / Equity1%
Profitability & ownership
ROE-26.4%
ROA-17.7%
% insiders0.2%
% institutions113.5%
Last declaration on 19 October 2026
Declarations120 total
1,000 shares@ US$0.600.0000% mcap0.1% of flowCommon StockSEC:0001193125-26-425295:0
500 shares@ US$61.650.0006% mcap3.1% of flowCommon StockSEC:0001193125-26-425295:1
500 shares@ US$62.480.0006% mcap3.1% of flowCommon StockSEC:0001193125-26-425295:2
3,000 shares@ US$61.840.0034% mcap21.3% of flowCommonSEC144:0001950047-26-010274
30,787 shares@ US$76.00690.043% mcap4.1% of flowCommonSEC144:0001950047-26-009691
6,532 shares@ US$76.500.0092% mcap0.9% of flowCommonSEC144:0001950047-26-009639
1,000 shares@ US$0.600.0000% mcap0.1% of flowCommon StockSEC:0001193125-26-394394:0
1,000 shares@ US$72.980.0013% mcap7.0% of flowCommon StockSEC:0001193125-26-394394:1
826 shares@ US$75.000.0011% mcap0.1% of flowCommonSEC144:0001950047-26-009375
50,000 shares@ US$75.5050.057% mcap6.6% of flowCommonSEC144:0001950047-26-008873
5,789 shares@ US$79.38520.0069% mcap0.8% of flowCommonSEC144:0001950047-26-008793
10,551 shares@ US$79.55060.013% mcap1.5% of flowCommonSEC144:0001950047-26-008678
5,762 shares@ US$79.51840.0069% mcap0.8% of flowCommonSEC144:0001950047-26-008634
100,000 shares@ US$79.54110.12% mcap13.9% of flowCommonSEC144:0001950047-26-008371
1,000 shares@ US$0.600.0000% mcap0.2% of flowCommon StockSEC:0001193125-26-355561:0
1,000 shares@ US$74.540.0011% mcap26.0% of flowCommon StockSEC:0001193125-26-355561:1
52,438 shares@ US$76.9460.061% mcap7.0% of flowCommonSEC144:0001950047-26-008205
19,364 shares@ US$75.01730.022% mcap2.5% of flowCommonSEC144:0001950047-26-008191
25,989 shares@ US$75.95410.030% mcap3.5% of flowCommonSEC144:0001950047-26-008109
32,137 shares@ US$78.6170.038% mcap4.4% of flowCommonSEC144:0001950047-26-008043
50,000 shares@ US$76.20510.058% mcap6.7% of flowCommonSEC144:0001950047-26-007989
50,000 shares@ US$75.41160.057% mcap6.6% of flowCommonSEC144:0001950047-26-007845
9,250 shares@ US$75.250.011% mcap1.2% of flowCommonSEC144:0001950047-26-007823
75,000 shares@ US$75.62950.086% mcap9.9% of flowCommonSEC144:0001950047-26-007736
25,000 shares@ US$73.500.028% mcap3.2% of flowCommonSEC144:0001950047-26-007711
25 of 120 declarations
About CG Oncology, Inc.
At CG Oncology, Inc., the purchases by Brian Guan-Chyun Liu (Director) stand out: EUR 42,608,485 on September 11, 2025 and EUR 21,840,443 on June 25, 2026. The fund Decheng Capital Global Life Sciences Fund IV, L.P. bought EUR 7,008,796 on January 29, 2024, a day when 4 insiders bought for EUR 11,677,915. The 6 purchases in the record total EUR 76.1 million, against 45 sales worth EUR 48.6 million (median EUR 63,230), or 12% purchases among open-market trades.
The sales are almost all by Hong Fang Song (Director): EUR 18,648,813 on December 16, 2024, EUR 13,537,410 on August 29, 2024 and EUR 7,219,941 on August 29, 2024. The rest of the record is 35 option exercises and 32 filings of another kind.
Read moreShow less
The 120 filings cover trades from January 29, 2024 to October 15, 2026, and 64 fall in 2026. Leonard E. Post (Director) is the most frequent with 42 filings, ahead of Ambaw Bellete (Officer) with 22. This healthcare company is worth USD 5.3 billion; 12 insiders are recorded. Last year: 66 filings, 1 purchase, 17 sales. Median publication delay: 1 day.
